Sensible Biotechnologies GTM brain

category

market profile

• text: mRNA therapeutic developers must manage impurities and immune activation that can constrain repeat dosing.
• text: Clinical-grade manufacturing depends on specialized inputs and scale-up, creating supply-chain and production risks.

personas

• title: Head of RNA Therapeutics R&D
  pains:

  • Candidate RNA triggers unwanted immune response
  • Sequence design and screening slow the search for viable therapies
• title: VP Process Development or CMC
  pains:

  • Moving RNA production toward clinical grade requires robust manufacturing and quality controls
  • Multiple specialized inputs create supply vulnerability
• title: Biotech business development leader
  pains:

  • Needs a differentiated RNA platform and a partner able to support development and scale
  • Must assess intellectual property and technical risk before a partnership

icp

• text: Biotech and pharmaceutical organizations developing mRNA medicines, particularly programs requiring repeat dosing.
• text: RNA platform teams evaluating linear, circular or self-amplifying modalities and manufacturing partners.

message pillars

• text: Integrate design and manufacturing in a cell-based platform.
• text: Address purity and immune response for therapeutic use.
• text: Support multiple RNA formats.

objections

• objection: Will cell-made RNA meet our clinical manufacturing requirements?
  response: Review process development, analytical comparability and clinical-grade readiness with the team for the specific program; the platform is still being scaled.
• objection: We already have an IVT process and established suppliers.
  response: Compare impurity, dosing and supply-chain tradeoffs with side-by-side program-specific data before switching.

competitors

• name: Moderna
  why: Develops mRNA medicines and proprietary manufacturing capabilities.
• name: Orna Therapeutics
  why: Develops an alternative RNA therapeutic platform.
• name: ReCode Therapeutics
  why: Develops RNA therapeutics and delivery technologies.

influencers

• name: Marian Kupculak
  url: https://uk.linkedin.com/in/marian-kupculak-34468a85
  why: Co-founder and CSO discussing the platform and partnerships.

keywords

• mRNA manufacturing platform
• cell based mRNA production
• mRNA immunogenicity
• RNA therapeutic development
• mRNA process development
• circular RNA manufacturing

voice

• Scientific and technically specific
• Ambitious and mission driven
• Comparative

signals

• text: A drug developer launches an mRNA program requiring repeat dosing or lower innate immune activation.
• text: An RNA biotech announces a CMC scale-up or seeks a manufacturing collaboration.

pricing

motion

channels

• scientific partnerships
• LinkedIn
• industry events
• press

confidence

Founders

• name: Miroslav Gasparek
  title: Founder
  role: Founder
  bio: I am Miro, CEO and Co-Founder of Sensible Biotechnologies. We build a cell-based platform for cost-efficient and scalable production of high-quality mRNA to unlock next generation of mRNA medicines. My background is in computational modeling of biological systems and bioengineering. I have worked on developing Slovak national biosecurity policies - I am passionate about building biotech ecosystem in Eastern Europe. I studied Bioengineering at Imperial College London and Engineering at Oxford.
• name: Marian Kupculak
  title: Founder
  role: Founder
  bio: I am Marian, the Chief Scientific Officer and co-founder of Sensible Biotechnologies. We are building a new platform for cost-efficient and scalable manufacturing of high-quality mRNA. I have more than 9 year of experience in biochemistry and molecular biology, more specifically in cellular engineering and downstream processing. I am interesting in engineering cells to produce high-quality proteins and nucleic acids. I did my PhD in Biochemistry at the University of Oxford, UK.